Study of noscapine in Buerger's disease

Evaluation of the effectiveness of noscapine capsules in patients with Buerger's disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180103038199N5

Enrollment

Registered

2021-05-12

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Buerger's disease. Thromboangiitis obliterans [Buerger's disease]

Interventions

Intervention group: receiving Noscapine 30 mg capsules twice daily for 60 days + Common treatment (including apixaban 5 mg/d and vitamin B1 300 mg/d).

Eligibility

Sex/Gender

All

Age

No minimum to 50 Years

Inclusion criteria

Inclusion criteria: less than 50 years old history of cigarette consumption Upper limb involvement or migratory thrombophlebitis Infra-popliteal vascular involvement

Exclusion criteria

Exclusion criteria: No burning pain and paresthesia at the time of referral Symptoms of allergies and drug allergies More than 2-fold increase in upper limit of liver enzymes More than 2-fold increase in upper limit of renal function parameters Lack of consent for continued intervention

Design outcomes

Primary

Measure	Time frame
Evaluation of pain using Visual Analogue Scale (VAS) scoring method. Timepoint: every week. Method of measurement: questionnaire of Visual Analogue Scale of pain.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Reza Askari

Mashhad University of Medical Sciences

askariv@mums.ac.ir+98 51 3800 2264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026